Clearmind Medicine
CMNDVancouver, United States· Est.
Public‑traded biotech creating non‑hallucinogenic psychedelic therapies for alcohol use disorder.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileCMND · Stock Price
USD 1.20+0.03 (+2.56%)
Market Cap: $2.9M
Historical price data
AI Company Overview
Public‑traded biotech creating non‑hallucinogenic psychedelic therapies for alcohol use disorder.
Alcohol Use DisorderAddictionMental Health
Technology Platform
Non‑hallucinogenic, second‑generation neuroplastogen‑derived psychedelics (e.g., MEAI) that modulate 5‑HT1A receptors to reduce cravings and impulsivity.
Opportunities
Large unmet AUD market and potential expansion to other binge‑behaviour disorders; first‑in‑class non‑hallucinogenic psychedelic could capture premium pricing and partnership interest.
Risk Factors
Clinical efficacy and safety uncertainty; regulatory hurdles for a novel psychedelic class; competition from established AUD therapies and other psychedelic developers.
Competitive Landscape
Competes with traditional AUD drugs (e.g., naltrexone) and psychedelic firms (MindMed, Compass Pathways); differentiation lies in non‑hallucinogenic oral formulation and safety profile.